News report
Sing Tao Front Page Exclusive Interview: 55% of New Lung Cancer Cases Are at Advanced Stages, Personalized Therapy Helps Reduce Recurrence Risk
Sing Tao Daily invited Dr. Li Yu Chung, Jacky to analyze lung cancer treatment trends. In 2022, 55% of new lung cancer cases reached stage IV, with a stage I survival rate of 72.4% compared to stage III's 24.6%. The Hong Kong United Cancer Centre provides genetic testing guidance...
Read more >>
TOPick Exclusive Interview: New Breakthrough in Stage 4 Lung Adenocarcinoma Treatment – Third-Generation Targeted Therapy Extends Survival by 38.6 Months
TOPick of Hong Kong Economic Journal invited Dr. Li Yu Chung, Jacky to analyze treatment regimens for lung adenocarcinoma. The median overall survival of third-generation targeted drugs reaches 38.6 months, while the efficacy rate of novel antibody-drug conjugate (ADC) targeted drugs is as high as 90% among patients with no smoking history. Hong Kong...
Read more >>
Am730_genic test is so useful _ Help you take the right medicine to treat metastatic colorectal cancer
Am730_genic test is so useful _ Help you take the right medicine to treat metastatic colorectal cancer
Read more >>
Am730 – Amgen's Precision Personalized Treatment: Bringing More Hope to Patients with Advanced Lung Cancer
Oriental Daily News_genic Testing Etiology MET Lung Cancer New News
Read more >>
Amgen-Dual chemotherapy plus targeted therapy improves the survival of advanced colorectal cancer
Oriental Daily News_genic Testing Etiology MET Lung Cancer New News
Read more >>
Oriental Daily News_genic Testing Etiology MET Lung Cancer New News
Oriental Daily News_genic Testing Etiology MET Lung Cancer New News
Read more >>